Introduction: To investigate the efficacy of a treatment strategy with latanoprost and
patients were Caucasian. Eighty percent of patients had bilateral glaucoma. Goniotomy was the most frequently performed surgery (38.6%), followed by trabeculotomy (22.8%), trabeculectomy (21.1%), and trabeculectomy plus trabeculotomy (17.5%). The baseline IOP was 23.6 ± 1.5 mmHg.
Conclusion:
The study population is representative of patients frequently encountered after the first surgery for primary pediatric glaucoma. The study will produce
INTRODUCTION
Pediatric glaucoma represents a group of potentially blinding diseases characterized by elevated intraocular pressure (IOP). The prognosis is largely dependent on early, accurate diagnosis and successful treatment that lowers IOP to levels where progression is unlikely [1] . Due to the rarity of these glaucomas, epidemiologic and prospective randomized studies are difficult to undertake.
According to the latest classification proposed by the World Glaucoma Association Consensus group, pediatric glaucoma is classified as primary or secondary [2] . In this classification, the term primary refers to glaucomas caused by anomaly of filtration angle, while secondary pediatric glaucoma is further classified according to whether the disease is acquired after birth or is present at birth (non-acquired). Non-acquired pediatric glaucoma is categorized according to whether the signs are mainly ocular or systemic.
Although surgery is the definitive treatment of choice for patients with pediatric glaucoma [3] [4] [5] [6] [7] [8] [9] [10] [11] , topical medications are usually also needed as temporary treatment before surgery or as adjunctive postoperative therapy [12, 13] . Beta blockers, carbonic anhydrase inhibitors (CAIs) and prostaglandins have all been used in the treatment of pediatric glaucomas [14] [15] [16] . Raber and colleagues reported on the safety of latanoprost exposure in a phase 1 study in pediatric and adult glaucoma patients [17] . The systemic exposure to latanoprost acid appeared higher in children than in adults, and suggested that this was due to lower body weight and a small blood volume in children [17] . This higher systemic exposure in children was not accompanied by adverse events, and thus there was an adequate safety margin for the use of an adult topical dose of latanoprost in children [17] . In a 12-week study, with pediatric glaucoma patients, latanoprost and 0.5% timolol were found to have similar efficacy and tolerability. Mean IOP reductions for latanoprost and timolol after 12 weeks were 7.2 and 5.7 mmHg, respectively. However, responder rates (subjects with IOP reduction of at least 15%) appeared to be low (60% for latanoprost and 52% for timolol) [18] .
Latanoprost and dorzolamide are commonly used in pediatric glaucoma patients due to their favorable efficacy and safety profile [14] [15] [16] [17] [19] [20] [21] [22] . At present, no data are available from prospective clinical trials on the efficacy and safety of a defined therapeutic strategy for the treatment of primary pediatric glaucoma (PPG). The Glaucoma Italian Pediatric Study (GIPSy) investigated the use of a specific therapeutic algorithm with latanoprost and dorzolamide in pediatric glaucoma patients partially responsive to surgery. This article reports the study protocol and baseline characteristics of study participants.
METHODS

Study Objective and Design
The GIPSy is a single arm, prospective, interventional study evaluating the IOP lowering effect of latanoprost and dorzolamide in PPG partially responsive to surgery.
Study Organization
Patient recruitment was performed in two institutions The following operations were allowed in the study: goniotomy, trabeculotomy, trabeculectomy with adjunctive mitomycin C, and trabeculectomy plus trabeculotomy with adjunctive mitomycin C. Study treatment was to be initiated at least 1 month after surgery. The second study visit was performed 60 days after the baseline visit. If the IOP decrease was major or equal to 20% with respect to baseline, treatment was continued.
Otherwise, the same approach described in visit 1 was followed. Eyes failing to reach a 20% IOP decrease from baseline under dorzolamide monotherapy were considered ''non-responders'', and treated at the physician's discretion. The treatment flow-chart is depicted in Fig. 1 .
The following visits were scheduled approximately every 60 days in the first year, every 90 days in the second year and every 120 days in the third year. The same algorithm, described above, for the allocation of patients in drug groups was followed in the following visits. The study treatment continued for 3 years or until treatment failure, whichever occurred first. If the patient was still in treatment at 3 years, a final visit was performed and the study was considered concluded.
Endpoints
The primary efficacy endpoint, calculated on a per-eye basis, was the percentage of ''responders'', defined as eyes with IOP reduction of at least 20% with respect to baseline. Secondary efficacy endpoint was the time to treatment failure, calculated as the time from the date of baseline visit to the date in which the medical treatment was discontinued due to failure to maintain adequate reduction of IOP.
Safety was assessed by evaluating the occurrence of serious and non-serious adverse events in general, and of the following events in particular: excessive eyelash growth (hypertrichosis), alterations of iris color, corneal epitheliopathy, allergic conjunctivitis and CCT changes.
Statistical Considerations
Statistical Methods
The per-protocol population included only eyes without major violation of eligibility criteria that received treatment according to the protocol schedule. All statistical analyses were based on the per-protocol population. Continuous variables were described using mean and standard deviation (SD), while categorical variables were described by means of frequencies and percentages of patients/eyes. The denominator for the percentage calculation was based on the total number of patients/eyes in each relevant analysis group. In all analyses, a p value\0.05 was considered significant.
Statistical analyses were performed using the SAS Ò System (v.9.4).
Sample Size Estimation
The sample size calculation was based on the primary endpoint. Using a Fleming single stage design, according to the A'Hern approach, setting the probability of erroneously concluding that the ''responder'' rate is greater than 35% at 5% (one-sided alpha = 0.05) and the probability of correctly concluding that the ''responder'' rate is at least 50% at 80% (beta error = 0.20), it was found necessary to include 68 eyes. The minimum number of ''responder'' eyes was set at 31 out of 68, since this result is associated with a lower limit of the 90% exact confidence interval (CI) of 35.2%. Since the number of eyes excluded from the per-protocol population was greater than expected, to analyze the primary outcome a recalculation of the achievable statistical power considering the actual number of analyzable eyes is needed. Out of 69 eyes, 4 were excluded from the per-protocol analysis because they had not undergone surgery and 8 because they were not treated with the study drugs. Therefore, 57 eyes of 35 patients were analyzed and are described in this report. Table 2 ).
The choice of glaucoma surgical treatment was based on disease severity and age at onset of SD standard deviation, Min-max minimum-maximum values At baseline, the IOP was measured in the sitting position in 11 (31.4%) patients and in the supine position in 24 (68.6%) patients (15 under general anesthesia; 9 awake).
DISCUSSION
GIPSy is a multicenter phase II interventional clinical trial that aims to evaluate the efficacy of medical treatment in a selected sample of predominantly Caucasian PPG patients partially responsive to a single surgical procedure. Patients with an IOP ranging from 22 to 26 mm Hg after a single surgical procedure were included in the study. This is a frequent IOP intra-ocular pressure, SD standard deviation, Min-max minimum-maximum values Thus, the choice of a prostaglandin analogue and carbonic anhydrase inhibitor was driven by the evidence of their efficacy in reducing IOP in adult glaucoma [26] and of their safety (local and systemic) [26, 27] . A goal of the current study was to define an effective therapeutic algorithm when a single surgical procedure was not able to achieve target IOP in patients affected by PPG.
The selection of the GIPSy population was defined in order to be highly representative of Caucasian PPG cases described in Europe. The mean age at presentation in the current study is comparable to that generally reported in the literature [28] [29] [30] [31] . Published evidence on gender predilection of PPG are also in agreement with our data which show a female\male ratio equal to 1:1.7. In agreement with previously published literature, most of our patients (80.0%) had bilateral glaucoma [13, 30, 32, 33] .
Compared to healthy adults, children with glaucoma have been reported to have thinner corneas [34, 35] . The mean CCT in the GIPSy was 561 lm and ranged from 485 to 674 lm. To date, no systematic investigations on CCT have been performed in adequately sized samples of patients with pediatric glaucoma. In adults, the average corneal thickness is approximately 520 lm at the center and approximately 700 lm at the periphery [36] . The CCT in newborns was found to be greater than 580 lm and decreased to adult values by 3 years of age [37, 38] . Doughty et al. [39] found similar mean CCT values in children 5-15 years of age compared to adults older than 32 years of age.
In a confocal microscopy study, Mastropasqua et al. [40] reported that the corneas in pediatric glaucoma patients have abnormal features in the Descemet membrane, stroma and endothelium. For example, the mean stromal keratocyte density was markedly reduced. The authors suggested that these findings were the direct result of corneal distention, which may explain why children with glaucoma have thinner corneas. Our data on CCT could be of interest in characterizing longitudinal changes in corneal thickness, and the eventual long-term effects of anti-glaucoma medications.
PPG patients recruited for this study were surgically treated according to current clinical practice. Angle surgeries (goniotomy and trabeculotomy) were performed in a large percentage of cases (61.4%) [23] .
The present study has limitations. First, the sample size is not particularly large. Recruiting adequately sized samples is an inevitable difficulty with trials investigating rare diseases, particularly when highly specialized centers and strict observation of study procedures are necessary. Second, the majority of participants were Caucasians. Consequently, the results of this study may not be generalizable to other ethnic groups.
By virtue of its design and population, the current study is representative of a clinical scenario encountered after the first surgery for PPG. Therefore, the results are expected to offer clinically relevant information on the utility of a defined pharmacological approach in the management of children with glaucoma.
CONCLUSION
The Glaucoma Italian Pediatric Study (GIPSy) investigated the use of a specific therapeutic algorithm with latanoprost and dorzolamide in pediatric glaucoma patients partially responsive to surgery. This article reports the study protocol and baseline characteristics of study participants. 
ACKNOWLEDGMENTS
